Results 31 to 40 of about 17,630,315 (317)

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American journal of hematology/oncology, 2023
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic ...
Andrew M. Brunner, Jordi Esteve, K. Porkka, S. Knapper, E. Traer, Sebastian Scholl, G. Garcia-Manero, N. Vey, M. Wermke, J. J. W. M. Janssen, Rupa Narayan, Shaun A Fleming, S. Loo, N. Tovar, M. Kontro, Oliver G. Ottmann, P. Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, C. Sabatos-Peyton, D. Steensma, Mikael L Rinne, U. Borate, Andrew H. Wei   +26 more
semanticscholar   +1 more source

The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells [PDF]

, 2016
The immune receptor Tim-3 is often highly expressed in human acute myeloid leukemia (AML) cells where it acts as a growth factor and inflammatory receptor.
Bardelli, Marco, Berger, Steffen M., Fasler-Kan, Elizaveta, Fruehwirth, Alexander, Gibbs, Bernhard F., Gonçalves Silva, Isabel, Rüegg, Laura, Sumbayev, Vadim V., Varani, Luca   +8 more
core   +1 more source

TIM-3 Regulates Distinct Functions in Macrophages [PDF]

Frontiers in Immunology, 2016
The transmembrane protein TIM-3 is a type I protein expressed by sub-types of lymphoid cells, such as lymphocytes Th1, Th17, Tc1, NK, as well as in myeloid cells. Scientific evidence indicates that this molecule acts as a negative regulator of T lymphocyte activation and that its expression is modified in viral infections or autoimmune diseases.
Ocaña-Guzman, Ranferi, Torre-Bouscoulet, Luis, Sada-Ovalle, Isabel   +2 more
openaire   +2 more sources

TIM-3 signaling hijacks the canonical Wnt/β-catenin pathway to maintain cancer stemness in acute myeloid leukemia

Blood Advances, 2023
Key Points • TIM-3/Gal-9 autocrine loop hijacks and constitutively activates canonical Wnt pathway in AML LSCs.• To hijack canonical Wnt pathway, HCK and p120-catenin, highly expressed on AML LSCs, play crucial roles in signal transduction of TIM-3.
Teppei Sakoda, Y. Kikushige, T. Miyamoto, Hidetoshi Irifune, T. Harada, Kiwamu Hatakeyama, Y. Kunisaki, Koji Kato, K. Akashi   +8 more
semanticscholar   +1 more source

Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. [PDF]

, 2017
Blockade of inhibitory receptors (IRs) overexpressed by T cells can activate antitumor immune responses, resulting in the most promising therapeutic approaches, particularly in bladder cancer, currently able to extend patient survival.
Bohner, P., Cesson, V., Chevalier, M.F., Dartiguenave, F., De Leval, L., Derré, L., Gharbi, D., Gourmaud, J., Jichlinski, P., Legris, A.S., Lhermitte, B., Martin, V., Nardelli-Haefliger, D., Nobile, A., Pieraerts, C., Rotman, S., Speiser, D.E.   +16 more
core   +1 more source

TIM-3 pathway dysregulation and targeting in cancer [PDF]

Expert Review of Anticancer Therapy, 2021
Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancies, but challenges such as limited response ...
Amer M, Zeidan, Rami S, Komrokji, Andrew M, Brunner   +2 more
openaire   +2 more sources

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma

Journal of Immunology Research, 2020
Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies.
Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang   +16 more
doaj   +1 more source

Association of TIM-3 expression with glucose metabolism in Jurkat T cells

BMC Immunology, 2020
Background T cell activation is associated with increase in glycolysis and glutaminolysis. T cell immunoglobulin and mucin domain containing protein-3 (TIM-3), a T cell surface molecule, downregulates T cell activation and leads to insufficient immunity ...
Mi Jin Lee, Su Jin Yun, Bokyoung Lee, Eun Jeong, Gyesoon Yoon, Kyongmin Kim, Sun Park   +6 more
doaj   +1 more source

The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.

Immunity, 2021
Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1+ classical dendritic cells (cDC1), thereby limiting antitumor immunity in mammary carcinomas.
Alvaro de Mingo Pulido, Kay Hänggi, Daiana P. Celias, Alycia Gardner, Jie-Hui Li, Bruna Batista-Bittencourt, Eslam Mohamed, J. Trillo-Tinoco, Olabisi Osunmakinde, Reymi Peña, Alexis Onimus, T. Kaisho, Johanna K. Kaufmann, K. McEachern, H. Soliman, V. Luca, P. Rodriguez, Xiaoqing Yu, B. Ruffell   +18 more
semanticscholar   +1 more source

Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy : TIM-3/galectin-9 interaction and its possible role during pregnancy [PDF]

, 2014
Problem: The T-cell immunoglobulin and mucin domain (TIM) family is a relatively newly described group of molecules with a conserved structure and important immunological functions. Identification of Galectin-9 as a ligand for TIM-3 has established the
Bogár, Barbara, Farkas, Bálint, Illés, Zsolt, Meggyes, Mátyás, Mikó, Éva, Polgár, Beáta, Szereday, László   +6 more
core   +1 more source